Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.58 |
| ▸ | WNT3A | P56704 | 3/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540656 | 1.00 | CTNNB1 (0.58) | CTNNB1WNT3ASMYD3TSHRKIF11 | |
| Hydrochloric Acid SCHEMBL31726879 | 0.98 | CTNNB1 (0.56) | CTNNB1WNT3ASMYD3TSHRKIF11 | |
| SCHEMBL15104920 | 0.89 | TSHR (0.53) | CTNNB1WNT3ASMYD3TSHRKIF11 | |
| SCHEMBL10407674 | 0.85 | CTNNB1 (0.61) | CTNNB1WNT3ASMYD3KIF11MRGPRX4 | |
| SCHEMBL3866171 | 0.83 | CTNNB1 (0.59) | CTNNB1WNT3ASMYD3KIF11MRGPRX4 | |
| SCHEMBL351400 | 0.83 | CTNNB1 (0.64) | CTNNB1WNT3ASMYD3TSHRMRGPRX4 | |
| SCHEMBL29746867 | 0.81 | TSHR (0.53) | CTNNB1WNT3ASMYD3TSHRKIF11 | |
| SCHEMBL1257050 | 0.81 | CTNNB1 (0.58) | CTNNB1WNT3ASMYD3KIF11MRGPRX4 | |
| SCHEMBL19160022 | 0.81 | CTNNB1 (0.58) | CTNNB1WNT3ASMYD3KIF11MRGPRX4 | |
| SCHEMBL1347343 | 0.81 | CTNNB1 (0.58) | CTNNB1WNT3ASMYD3MRGPRX4HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010017179-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| CN-116730995-A | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-9145373-B2 | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2331095-B1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-1739082-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | Agouron Pharmaceuticals , Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7094909-B2 | Reacting an amide compound containing hydroxy and a carboxyl group and having benzene ring, with a halogenated alkyl aminocarbonyl-pyrrolidine with 2-fluoro groups substituted at the ring carbon, by amindation of amine and carboxyl group | AGOURON PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20050250707-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2005-11-10 | — | — | US | disclosed |
| US-6953858-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| EP-1448539-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | Agouron Pharmaceuticals , Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PFIZER INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030153507-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2002100845-A1 | HV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153507-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, FURIN, PEPD | CTNNB1 3017/4885WNT3A 3462/4885SMYD3 3483/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | CTNNB1 2934/4885WNT3A 3138/4885SMYD3 1/4885 |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | SERPINB1, PEPD, PREP | CTNNB1 2885/4885WNT3A 3422/4885SMYD3 3339/4885 |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, FURIN, PEPD | CTNNB1 3017/4885WNT3A 3462/4885SMYD3 3483/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | CTNNB1 3844/4885WNT3A 4226/4885SMYD3 1/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | CTNNB1 3866/4885WNT3A 4231/4885SMYD3 1/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | CTNNB1 3361/4885WNT3A 4243/4885SMYD3 2/4885 |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | FURIN, PREP, PRSS1 | CTNNB1 2626/4885WNT3A 3069/4885SMYD3 1885/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | CTNNB1 3894/4885WNT3A 4249/4885SMYD3 1/4885 |
| US-20050250707-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | CTNNB1 3054/4885WNT3A 3550/4885SMYD3 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.